Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

MORE HEADLINES

» Markets | Economy | Companies

- Thanksgiving Week Stuffed With Economic News

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Friday At The Fat Fight

Published: Friday, 30 Oct 2009 | 12:46 PM ET

Text Size

By: Mike Huckman
CNBC Correspondent

I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.

On Monday I was reporting and blogging from the Obesity Society meeting in Washington, DC where I highlighted all three players—Vivus, Arena Pharmaceuticals and Orexigen Therapeutics.

ARNA [ARNA Loading... () ] and OREX [OREX Loading... () ] put out press releases on the new data they presented at the conference. Vivus [VVUS Loading... () ] didn't. In fact, we were told by a company spokesperson there was nothing new.

Then, on Tuesday Cowen and Company biotech analyst Ian Sanderson wrote a research note for clients raising a red flag about a piece of VVUS' presentation. The stock fell. The conference ended Wednesday. Everyone went home.

AP
For scientific and medical meetings like this one companies typically issue curtain-raiser press releases in advance of the event. In other words, they tell everyone, "Here's what we're gonna have new for you at thus-and-such meeting."

Then, as soon as the data are presented and the media embargo lifts companies immediately put out another press release with the new stuff they promised.

Not Vivus.

It waited five days after unveiling its data and one day after the meeting had ended to get around to putting out a press release after the closing bell on Thursday. The stock popped in after-hours trading and it's higher so far today, so maybe the company accomplished what it set out to do. But I can't imagine any media outlet that's been closely following the fat fight doing anything with the information.

All three companies are close to filing for FDA approval of their drugs and are on the prowl for big corporate partners.

If what went down this week is any indication this is gonna be a battle of the bulge royale.

Questions? Comments? and follow me on Twitter at mhuckman